Compare ONC & KB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONC | KB |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Switzerland | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8B | 31.3B |
| IPO Year | N/A | 2008 |
| Metric | ONC | KB |
|---|---|---|
| Price | $317.89 | $109.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $377.33 | N/A |
| AVG Volume (30 Days) | 234.7K | ★ 267.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $770.07 | $19.37 |
| Revenue Next Year | $15.48 | $3.03 |
| P/E Ratio | $614.06 | ★ $9.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $196.53 | $46.38 |
| 52 Week High | $385.22 | $119.71 |
| Indicator | ONC | KB |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 56.60 |
| Support Level | $307.93 | $78.61 |
| Resistance Level | $350.56 | N/A |
| Average True Range (ATR) | 10.46 | 2.79 |
| MACD | -4.21 | -0.30 |
| Stochastic Oscillator | 6.49 | 39.47 |
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.